Note: may require registration (free):
"The results of the JGOG (Japanese) trial in ovarian cancer (Oct 17, p 1331)
show a significant benefit in terms of progression-free survival in the
group on adjuvant weekly high-dose paclitaxel. Such improvements are in
the magnitude of those achieved by the introduction of platinum
compounds. However, some features of the JGOG study should be
highlighted...."
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.